PRINCETON, N.J. / Sep 19, 2025 / Business Wire / Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.
About Bristol Myers Squibb: Transforming Patients’ Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.
corporatefinancial-news
| Last Trade: | US$53.95 |
| Daily Change: | -0.26 -0.48 |
| Daily Volume: | 7,135,701 |
| Market Cap: | US$110.060B |
December 08, 2025 December 03, 2025 December 01, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
